Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.
about
Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingTailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational studyEffects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammationCan We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference BehaviorExpression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.Systemic arteriosclerosis and eating behavior in Japanese type 2 diabetic patients with visceral fat accumulationLiraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes.Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity.Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection.Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes.Incretin hormones and the satiation signal.Obesity consults--comprehensive obesity management in 2013: understanding the shifting paradigm.GLP-1: benefits beyond pancreas.Liraglutide: a review of its use in the management of obesity.Abdominal adiposity contributes to adverse glycemic control and albuminuria in Chinese type 2 diabetic patients: A cross-sectional study.Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.Exendin-4 reduces food intake via the PI3K/AKT signaling pathway in the hypothalamus.Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression.Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.Changes in Energy Metabolism after Continuous Positive Airway Pressure for Obstructive Sleep Apnea.Study protocol: a randomised controlled trial of supervised resistance training versus aerobic training in Sri Lankan adults with type 2 diabetes mellitus: SL-DART study.Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.Centrally Acting Agents for Obesity: Past, Present, and Future
P2860
Q26992979-C548978F-FFC7-4C41-AE12-DBB74BEFB493Q33890570-24DBEF59-AE2C-4CE8-873F-F9B7AF0CE04DQ34202922-2E486DD1-6C9E-47DE-9799-8313F0D83DCCQ34405101-5F0CA4B8-2815-4F41-8EB4-47F4BCBBE9CEQ34501087-DCD1DF32-3ECA-4797-8003-3B953DA2082CQ34745109-9B005F79-4047-4A7C-BC01-F3BB125F1018Q34994425-1918C55D-6247-4A56-B09B-33AF9A2F8A58Q35438220-242E192D-97B2-4702-8301-94E0004CE95FQ35861339-58430811-6A1D-4D91-B446-CECF83D425CEQ36284121-86EE340A-31CE-413D-9D5C-9B31D7E2948BQ36498624-760426CD-5A52-4C78-8D20-5AEA07DFD2A5Q36757419-636C9286-B1C0-4355-8548-058A4668186DQ36972569-4A995788-2513-45D8-9FE5-56125891EF99Q36980756-2D8E753E-602B-46D0-9760-D89471EC177DQ37581317-B038CD97-6169-4771-9D2D-243B7029663AQ37736845-44B0E123-0FE3-44B2-8EA9-4DF6E7E58816Q38072203-6A7F5063-A371-4B78-B5B3-D91F36F68030Q38164632-D65F2209-63B7-4D0B-BEEA-D1CB49B635CFQ38238288-DBB635C6-0F37-4A92-8564-F78A41709AD8Q38488650-95098479-642A-4028-AD0D-CBEFE02DE09AQ39834166-29F811B2-F0FD-4757-B484-CA875380428BQ40988787-5D2D9308-ABEE-44DB-BB19-719C588F00B3Q41191799-2C6B920E-8FBA-4069-B319-B9DB661D8A8EQ42037657-AF0EC059-DA21-4F6C-8DB9-948491C4C69EQ47594612-66E8851C-10C4-472D-92C0-A2D32868CB67Q47882171-13B911D9-A7E0-45A6-8630-0ECB86FD2F5BQ49470693-BB347F55-E1B9-43EB-AA62-E132ABAF018DQ51316530-22284425-8514-487A-A564-B3D2E8D5D146Q52338665-092F660B-2D7C-4B6A-9DEF-B1499BED26CCQ52654943-BCE55343-57BE-45FE-A029-509CD5E7AA7DQ57177981-EEF0EB56-94AA-4AEE-B91F-6D574FA3421C
P2860
Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Short-term effects of liraglut ...... patients with type 2 diabetes.
@ast
Short-term effects of liraglut ...... patients with type 2 diabetes.
@en
type
label
Short-term effects of liraglut ...... patients with type 2 diabetes.
@ast
Short-term effects of liraglut ...... patients with type 2 diabetes.
@en
prefLabel
Short-term effects of liraglut ...... patients with type 2 diabetes.
@ast
Short-term effects of liraglut ...... patients with type 2 diabetes.
@en
P2093
P2860
P921
P356
P1476
Short-term effects of liraglut ...... patients with type 2 diabetes.
@en
P2093
Aki Hiuge-Shimizu
Akihisa Imagawa
Iichiro Shimomura
Junji Kozawa
Kana Inoue
Kohei Okita
Norikazu Maeda
Susumu Kashine
Tohru Funahashi
Yuya Fujishima
P2860
P2888
P356
10.1186/1475-2840-10-109
P407
P577
2011-12-01T00:00:00Z
P5875
P6179
1034904407